Prognostic factors for the breast cancer patients with bone metastasis

Abstract

835 Background: Median survival for breast cancer patients with bone metastasis is 2 years. Factors affecting the prognosis after bone metastasis are not clear. Methods: In this study, 141 metastatic breast cancer patients who have disease in bone and were followed in Hacettepe University Faculty of Medicine, Department of Medical Oncology between 1990 and 2003 were evaluated for the prognostic factors. Results: The median overall survival (OS) was 68.4 months, the disease free survival (DFS) was 21.3 months, the bone metastasis free survival (BFS) was 23.3 months and overall survival after bone metastasis (BOS) was 28.4 months. In univariate analyses statistically significant predictors for OS and DFS were the size of the primary tumor, presence of lymphovascular invasion and the site of the first metastasis, for BFS were the size of the primary tumor, number of the metastatic lymph nodes and presence of lymphovascular invasion and finally for BOS were the size of the primary tumor, presence of lymphovascular invasion, nuclear and histological grade of tumor, receptor status and development of subsequent any visceral metastasis after first bone metastasis only. In multivariate analyses, the size of the primary tumor was the significant independent prognostic factor for all OS, DFS and BFS, Presence of LVI was the significant independent prognostic factor for OS and BOS. Conclusions: In the result of study, for patients with breast cancer, survival after bone metastasis is affected by primary prognostic factors. No significant financial relationships to disclose.